



ZIOPHARM Oncology, Inc.  
 Investor Relations Department  
 One First Ave., Parris Building, # 34  
 Navy Yard Plaza  
 Boston, MA 02199  
 United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: ZIOP**

Last Trade:	5.71
Trade Time:	4:00 PM ET Oct 17, 2017
Change:	0.08 (+1.421%)
Day Range	5.63 - 5.77
52-Week Range	4.89 - 7.88
Volume	1,146,077

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Oct 16, 2017*  
[ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors](#)
- Oct 12, 2017*  
[ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology](#)
- Sep 28, 2017*  
[ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer](#)
- Sep 18, 2017*  
[ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting](#)
- Sep 5, 2017*  
[ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference](#)

**Financials** [\[ View all \]](#)

- Feb 16, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Jul 31, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*  
[Quarterly Report \(10-Q\)](#)